$BPTH
BIO-PATH HOLDINGS, INC.

2023 Q2 Form 10-Q Financial Statement

#000155837023009382 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.191M $1.303M
YoY Change 2.76% 3.33%
% of Gross Profit
Research & Development $3.051M $3.989M
YoY Change 64.83% 90.13%
% of Gross Profit
Depreciation & Amortization $22.00K $22.00K
YoY Change 4.76% 0.0%
% of Gross Profit
Operating Expenses $4.242M $5.292M
YoY Change 40.93% 57.55%
Operating Profit -$4.242M -$5.292M
YoY Change 40.93% 57.55%
Interest Expense $8.000K $19.00K
YoY Change 300.0%
% of Operating Profit
Other Income/Expense, Net $8.000K $19.00K
YoY Change 300.0%
Pretax Income -$4.234M -$5.273M
YoY Change 40.76% 56.98%
Income Tax
% Of Pretax Income
Net Earnings -$4.234M -$5.273M
YoY Change 40.76% 56.98%
Net Earnings / Revenue
Basic Earnings Per Share -$0.53 -$0.66
Diluted Earnings Per Share -$0.53 -$0.66
COMMON SHARES
Basic Shares Outstanding 7.960M 7.960M
Diluted Shares Outstanding 7.960M 7.960M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.444M $6.731M
YoY Change -79.77% -68.32%
Cash & Equivalents $3.444M $6.731M
Short-Term Investments
Other Short-Term Assets $1.746M $1.664M
YoY Change 25.43% 18.01%
Inventory
Prepaid Expenses $1.069M $2.396M
Receivables
Other Receivables
Total Short-Term Assets $6.259M $10.79M
YoY Change -69.56% -54.29%
LONG-TERM ASSETS
Property, Plant & Equipment $114.0K $136.0K
YoY Change -43.84% -33.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $265.0K $311.0K
YoY Change -40.58% -33.55%
TOTAL ASSETS
Total Short-Term Assets $6.259M $10.79M
Total Long-Term Assets $265.0K $311.0K
Total Assets $6.524M $11.10M
YoY Change -68.95% -53.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $638.0K $827.0K
YoY Change 6.33% 106.75%
Accrued Expenses $675.0K $973.0K
YoY Change 12.5% -11.55%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.426M $1.910M
YoY Change 7.95% 21.81%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $55.00K $85.00K
YoY Change -67.26% -56.41%
Total Long-Term Liabilities $55.00K $85.00K
YoY Change -67.26% -56.41%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.426M $1.910M
Total Long-Term Liabilities $55.00K $85.00K
Total Liabilities $1.481M $1.995M
YoY Change -0.54% 13.16%
SHAREHOLDERS EQUITY
Retained Earnings -$101.0M -$96.80M
YoY Change 20.24% 19.48%
Common Stock $8.000K $8.000K
YoY Change 14.29% 14.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.043M $9.107M
YoY Change
Total Liabilities & Shareholders Equity $6.524M $11.10M
YoY Change -68.95% -53.89%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$4.234M -$5.273M
YoY Change 40.76% 56.98%
Depreciation, Depletion And Amortization $22.00K $22.00K
YoY Change 4.76% 0.0%
Cash From Operating Activities -$3.287M -$3.653M
YoY Change -21.79% 44.62%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -3.287M -3.653M
Cash From Investing Activities 0.000
Cash From Financing Activities
Net Change In Cash -3.287M -3.653M
YoY Change -22.18% 44.62%
FREE CASH FLOW
Cash From Operating Activities -$3.287M -$3.653M
Capital Expenditures $0.00
Free Cash Flow -$3.287M
YoY Change -21.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7960000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7160000
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7160000
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7960000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7160000
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
BIO-PATH HOLDINGS INC
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001133818
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Cash
Cash
6700000
CY2023Q1 dei Entity File Number
EntityFileNumber
001-36333
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0652870
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
4710 Bellaire Boulevard, Suite 210
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Bellaire
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77401
CY2023Q1 dei City Area Code
CityAreaCode
832
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
742-1357
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
BPTH
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7960164
CY2023Q1 us-gaap Cash
Cash
6731000
CY2022Q4 us-gaap Cash
Cash
10384000
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2396000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3587000
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
1664000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1644000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
10791000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
15615000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1120000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1120000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
984000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
962000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
136000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
158000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
175000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
198000
CY2023Q1 us-gaap Assets
Assets
11102000
CY2022Q4 us-gaap Assets
Assets
15971000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
827000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
667000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
973000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
909000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
110000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
108000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1910000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1684000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
85000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
113000
CY2023Q1 us-gaap Liabilities
Liabilities
1995000
CY2022Q4 us-gaap Liabilities
Liabilities
1797000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7960000
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
8000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
105901000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
105695000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-96802000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91529000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
9107000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
14174000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11102000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15971000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3989000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2098000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1303000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1261000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
5292000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
3359000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5292000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3359000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
19000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
19000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5273000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3359000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7960000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7160000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5273000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3359000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
206000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
217000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
23000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
23000
CY2023Q1 us-gaap Depreciation
Depreciation
22000
CY2022Q1 us-gaap Depreciation
Depreciation
22000
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1191000
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
429000
CY2023Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
20000
CY2022Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-433000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
224000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
591000
CY2023Q1 bpth Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
26000
CY2022Q1 bpth Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
24000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3653000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2526000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3653000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2526000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10384000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23774000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6731000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21248000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
85000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
25457000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
217000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3359000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
22315000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
14174000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
206000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5273000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
9107000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
3600000
CY2023Q1 bpth Expected Advanced Payment To Be Expensed
ExpectedAdvancedPaymentToBeExpensed
2400000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
200000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
200000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0243
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.27
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
658000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.67
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
658000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.67
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
640000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
11.85
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
393000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
16.08
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1100000
CY2023Q1 bpth Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Unvested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndUnvestedWeightedAverageRemainingContractualTerm
P2Y1M6D
CY2023Q1 us-gaap Other Commitment Due In Next Twelve Months
OtherCommitmentDueInNextTwelveMonths
2100000

Files In Submission

Name View Source Status
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
0001558370-23-009382-index-headers.html Edgar Link pending
0001558370-23-009382-index.html Edgar Link pending
0001558370-23-009382.txt Edgar Link pending
0001558370-23-009382-xbrl.zip Edgar Link pending
bpth-20230331.xsd Edgar Link pending
bpth-20230331x10q.htm Edgar Link pending
bpth-20230331xex31.htm Edgar Link pending
bpth-20230331xex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
bpth-20230331_cal.xml Edgar Link unprocessable
bpth-20230331_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bpth-20230331_lab.xml Edgar Link unprocessable
bpth-20230331_pre.xml Edgar Link unprocessable
bpth-20230331x10q_htm.xml Edgar Link completed